Drugs / Acetaminophen
Acetaminophen
also known as
paracetamol · Tylenol · APAP · acetominophen · Ofirmev · Panadol · Parol · Acetaminophen ER · +147 more
Small molecule targets FAAH, TRPV1 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | OFIRMEV | — | 2017-01-27 | fda.gov ↗ |
| Approved | US (FDA) | NEOPAP | — | 1968-11-07 | fda.gov ↗ |
Trials 569 · started per year
today
US approved 1968
1
1
1
1
1
1
1
3
10
7
12
12
19
24
19
15
17
11
33
25
25
28
31
45
37
33
23
29
20
23
20
22
19
19681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 015 trials · 1 met primary · 2 missed | ||||||
| Phase 0 | NCT06462573 | Sep 2024 → Sep 2026 overdue | ureterolithiasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06561672 | Sep 2024 → Mar 2025 overdue | — | Zagazig University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06514222 | Jul → Aug 2024 overdue | impacted teeth, multiple | University of Sharjah | Active not recruiting | Missed primary |
| Phase 0 | NCT06294743 | Nov 2023 → Dec 2025 | dysmenorrhea | Taichung Armed Forces General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05122351 | Oct 2021 → Dec 2022 | — | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT04612920 | Dec 2020 → Mar 2023 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 0 | NCT04648540 | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT04059172 | Dec 2019 → Jun 2028 expected | persistent idiopathic facial pain | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 0 | NCT03763084 | Feb 2019 → Feb 2020 | delirium, paracetamol poisoning | Xiangya Hospital of Central South University | Unknown | Missed primary |
| Phase 0 | NCT03820193 | Jan 2019 → Jun 2020 | substance-related disorder | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT03878693 | Jul → Oct 2018 | — | University of Arizona | Completed | Met primary |
| Phase 0 | NCT03383133 | Jan 2018 → Feb 2023 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT02540512 | Jul → Sep 2017 | musculoskeletal system disorder | Loma Linda University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03221998 | Jul 2017 → Mar 2019 | morbid obesity | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT02366065 | Jan 2015 → May 2016 | glaucoma | Johns Hopkins University | Completed | No outcome recorded |
| Phase 171 trials · 2 met primary | ||||||
| Phase 1 | NCT07845578 | Sep 2026 → Sep 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07824258 | Sep 2026 → Dec 2030 expected | — | Columbia University | Recruiting | No outcome recorded |
| Phase 1 | NCT07710729 | Jul 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07632274 | Jun → Sep 2026 overdue | — | HALEON | Recruiting | No outcome recorded |
| Phase 1 | NCT07502001 | Apr → Dec 2026 expected | obesity disorder | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07525791 | Apr 2026 → May 2027 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07269756 | Dec 2025 → Mar 2026 | obesity disorder | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07429032 | Apr → Nov 2025 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT06920056 | Mar → Jul 2025 | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06701305 | Jun 2024 → Feb 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06214468 | Jan 2024 → Apr 2025 | poisoning | University of South Alabama | Completed | No outcome recorded |
| Phase 1 | NCT06186622 | Jan → Jul 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06137469 | Dec 2023 → Mar 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06036784 | Sep 2023 → Nov 2024 | postgastrectomy syndrome | MBX Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05844995 | Sep 2023 → Feb 2024 | — | Johnson & Johnson Consumer Inc. (J&JCI) | Completed | No outcome recorded |
| Phase 1 | NCT07095816 | May 2023 → Feb 2025 | neoplasm | Nanjing Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05995704 | Mar → Jul 2023 | — | VectivBio AG | Completed | No outcome recorded |
| Phase 1 | NCT05564819 | Sep 2022 → May 2023 | childhood acute lymphoblastic leukemia | Nanjing Children's Hospital | Completed | Met primary |
| Phase 1 | NCT05406752 | Jul 2022 | — | Unither Pharmaceuticals, France | Completed | No outcome recorded |
| Phase 1 | NCT04741139 | Sep 2021 → Dec 2022 | autoimmune thrombocytopenia | Baylor College of Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT04941040 | Jul → Oct 2021 | supratentorial cancer | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04571996 | Oct 2020 → Feb 2021 | central nervous system disorder | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT06782204 | Jul 2020 → Jan 2021 | hypertensive disorder | Hospital da Luz, Portugal | Completed | No outcome recorded |
| Phase 1 | NCT04265456 | Jan → Jun 2020 | — | Nevakar, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04230252 | Jan → Feb 2020 | — | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 1 | NCT04214691 | Dec 2019 → Jan 2020 | — | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 1 | NCT04424420 | Nov 2019 → Mar 2021 | — | Prof. Jürgen Brockmöller | Unknown | No outcome recorded |
| Phase 1 | NCT03953287 | Aug → Dec 2019 | — | Kolding Sygehus | Unknown | No outcome recorded |
| Phase 1 | NCT05428306 | Oct → Nov 2018 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03648437 | Sep 2018 → Oct 2024 | patent ductus arteriosus | University of Oulu | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03415243 | Mar 2018 | common cold | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03137030 | Sep 2017 → Jan 2018 | substance-related disorder | Grünenthal GmbH | Withdrawn | No outcome recorded |
| Phase 1 | NCT03103022 | Jun 2017 → Apr 2019 | patent ductus arteriosus | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT03182595 | Mar 2017 → Jan 2018 | — | Hospital da Luz, Portugal | Completed | No outcome recorded |
| Phase 1 | NCT02966860 | Aug → Sep 2016 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT02618395 | Dec 2015 → Jan 2016 | — | Sun Pharma Advanced Research Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02641899 | Dec 2015 → Mar 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02174068 | Jul 2014 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT02305017 | Mar → Apr 2014 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02206178 | Sep 2013 → Jan 2014 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT02095704 | May 2013 | — | Central South University | Completed | No outcome recorded |
| Phase 1 | NCT03223506 | Mar 2013 → Dec 2017 | brain injury | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02561741 | Dec 2012 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT01734759 | Nov 2012 → Jan 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01606059 | May → Jun 2012 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01562704 | Jan → Apr 2012 | pain agnosia | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT01880125 | Jan → May 2012 | — | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01520792 | Nov 2011 → May 2013 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT01211912 | Sep 2010 → Dec 2011 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01188525 | Aug 2010 → Jul 2011 | — | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 1 | NCT01767428 | Apr 2010 | headache disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01053650 | Jan → Feb 2010 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT01540734 | Dec 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01592227 | Dec 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01476189 | Nov → Dec 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01476215 | Nov 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00982215 | Sep → Oct 2009 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT01476176 | Jul → Aug 2009 | headache disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01551836 | Jun 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00750048 | Sep → Nov 2008 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00750347 | Sep → Oct 2008 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00772967 | Jun → Nov 2008 | osteoarthritis | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 1 | NCT00973232 | May → Aug 2008 | — | Labopharm Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02514941 | Jun 2007 → Mar 2010 | morbid obesity | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT00493246 | Jun 2007 → Nov 2008 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT01116596 | Feb 2007 → Feb 2008 | chronic pain syndrome | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00429468 | Jan 2007 → ? | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00428909 | Nov 2006 → Aug 2008 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00411190 | Oct → Dec 2006 | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01517555 | Oct 2006 → May 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 1 | NCT00653315 | May → Aug 2002 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1/211 trials | ||||||
| Phase 1/2 | NCT06256211 | Mar → Nov 2024 | patent ductus arteriosus | Soha mahmoud Hussien mahdy | Unknown | No outcome recorded |
| Phase 1/2 | NCT05742763 | Nov 2023 → Oct 2024 | osteoarthritis, knee | QC Kinetix LLC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04015557 | Feb → Jun 2022 | classic homocystinuria | Hospital de Clinicas de Porto Alegre | Suspended | No outcome recorded |
| Phase 1/2 | NCT03997851 | Jul 2019 → Mar 2020 | — | University of Miami | Completed | No outcome recorded |
| Phase 1/2 | NCT03641209 | Sep 2018 → Nov 2023 | — | Outi Aikio | Completed | No outcome recorded |
| Phase 1/2 | NCT03617900 | Aug 2018 → May 2019 | puerperal disorder | Thammasat University | Completed | No outcome recorded |
| Phase 1/2 | NCT03528343 | Sep → Dec 2017 | appendicitis | University of Utah | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03184649 | May → Sep 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02654860 | Nov 2016 → Feb 2019 | — | Sintetica SA | Completed | No outcome recorded |
| Phase 1/2 | NCT01026961 | Sep → Nov 2010 | — | Novartis | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01086722 | Feb 2010 → Feb 2013 | morbid obesity | Hospital del Mar Medical Research Institute (IMIM) | Completed | No outcome recorded |
| Phase 260 trials · 9 met primary · 7 missed | ||||||
| Phase 2 | NCT06689943 | Apr 2025 → Dec 2028 expected | strabismus | Ann & Robert H Lurie Children's Hospital of Chicago | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05685225 | Jan → Dec 2025 | migraine disorder | Allodynic Therapeutics, Inc | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06658574 | Nov 2024 → May 2026 | — | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT06345716 | Apr 2024 → Mar 2025 overdue | urinary tract obstruction | University of Monastir | Recruiting | No outcome recorded |
| Phase 2 | NCT05477875 | Feb 2024 → Jan 2025 | hyperopia, myopia | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT06009926 | Dec 2023 → Feb 2026 overdue | cancer, hematopoietic and lymphoid system neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06152796 | Dec 2023 → Sep 2025 | patent ductus arteriosus | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT07528118 | Aug 2023 → Jun 2024 | — | Sargodha Medical College | Completed | No outcome recorded |
| Phase 2 | NCT05340582 | Dec 2022 → Jan 2027 expected | patent ductus arteriosus | Mount Sinai Hospital, Canada | Recruiting | No outcome recorded |
| Phase 2 | NCT06371144 | Jun → Sep 2022 | — | Darlington-Peter Chibuzor Ugoji | Completed | No outcome recorded |
| Phase 2 | NCT04676802 | Dec 2021 → Feb 2027 expected | neuropathy, painful, osteoarthritis, hand | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT03792295 | Jul → Dec 2021 | — | Khashayar Vaziri | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04447040 | Nov 2020 → Apr 2021 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | Met primary |
| Phase 2 | NCT04221165 | Aug 2020 → Sep 2023 | head and neck cancer, mucositis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | Met primary |
| Phase 2 | NCT04495283 | Jul → Nov 2020 | — | Nevakar, Inc. | Completed | Met primary |
| Phase 2 | NCT05764707 | Jan 2020 → Jan 2023 | vertebral column disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03879408 | May → Nov 2019 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 2 | NCT03767933 | Apr 2019 → Mar 2023 | musculoskeletal system disorder | University of Alberta | Completed | Missed primary |
| Phase 2 | NCT03679013 | Apr → Jul 2019 | — | Inova Health Care Services | Completed | No outcome recorded |
| Phase 2 | NCT03818919 | Jan 2019 → Dec 2020 | rotator cuff syndrome | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2 | NCT03399318 | Jan 2019 → Dec 2022 | epilepsy, malaria, parasitemia | University of Rochester | Completed | Met primary |
| Phase 2 | NCT03701074 | Dec 2018 → Oct 2020 | bronchopulmonary dysplasia, patent ductus arteriosus | University of South Alabama | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03559985 | Aug 2018 → Oct 2020 | neuropathy, painful | University Hospital, Clermont-Ferrand | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03521102 | Aug 2018 → Oct 2021 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03428230 | Aug 2018 → Oct 2019 | neuropathy, painful | Sintetica SA | Completed | No outcome recorded |
| Phase 2 | NCT03570554 | Jun 2018 → Jun 2019 | osteoarthritis, knee | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT03652818 | Jun → Sep 2018 | dental pulp disorder | Nevakar, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03635684 | May 2018 → Jun 2020 | — | Saint-Joseph University | Completed | No outcome recorded |
| Phase 2 | NCT03194555 | Aug 2017 → Jul 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | Missed primary |
| Phase 2 | NCT03201393 | Aug 2017 → Jul 2018 | chronic pain syndrome, radiculopathy | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT06245902 | Feb 2017 → Feb 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT03061734 | Feb 2017 → Feb 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02625454 | Dec 2016 → May 2019 | — | Richmond University Medical Center | Unknown | Missed primary |
| Phase 2 | NCT02422966 | Dec 2015 → Jan 2019 | patent ductus arteriosus | Angelini Pharma | Completed | Missed primary |
| Phase 2 | NCT02532322 | Nov 2015 → Jun 2018 | Chiari malformation, childhood infratentorial neoplasm | Children's National Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT02578251 | Oct 2015 → Mar 2016 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02320708 | Dec 2014 → Apr 2015 | — | Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02133326 | Mar 2014 → Jan 2017 | impacted teeth, multiple | Tufts University School of Dental Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT02815189 | Feb 2014 → Feb 2016 | — | Universidad Autonoma de Baja California | Completed | No outcome recorded |
| Phase 2 | NCT01958320 | Dec 2013 → Jun 2017 | intestinal perforation, necrotizing enterocolitis, patent ductus arteriosus | University of California, San Francisco | Completed | Missed primary |
| Phase 2 | NCT01960114 | Oct 2013 → Apr 2014 | dental pulp disorder | McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. | Completed | Met primary |
| Phase 2 | NCT02108990 | Sep 2013 → Jun 2014 | borderline personality disorder | Ohio State University | Completed | No outcome recorded |
| Phase 2 | NCT01938261 | Aug 2013 → Jul 2024 | patent ductus arteriosus | University of Oulu | Completed | Met primary |
| Phase 2 | NCT01739361 | Apr → Dec 2013 | infectious disease with sepsis | Vanderbilt University | Completed | Missed primary |
| Phase 2 | NCT01691690 | Oct 2012 → Nov 2015 | tonsillitis | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02417337 | Aug 2012 → Aug 2014 | pulpitis | University of Khartoum | Completed | No outcome recorded |
| Phase 2 | NCT01906762 | Jul 2012 → Feb 2013 | urinary system disorder | Seyed Mehdi Pourafzali | Completed | No outcome recorded |
| Phase 2 | NCT01559259 | Apr → Sep 2012 | — | Pfizer | Completed | Met primary |
| Phase 2 | NCT01291654 | Apr 2012 → Dec 2014 | patent ductus arteriosus | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01231139 | Oct 2010 → Dec 2013 | traumatic brain injury | Dr. M.K. Saxena | Completed | No outcome recorded |
| Phase 2 | NCT01630343 | Jan 2010 → Apr 2012 | — | Queen Elizabeth Hospital, Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT00758836 | Dec 2008 → Aug 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2 | NCT00841841 | Mar 2006 → Mar 2008 | — | University Center of Araraquara | Completed | No outcome recorded |
| Phase 2 | NCT00281684 | Dec 2005 → Oct 2007 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00528658 | Jan 2005 → Dec 2008 | — | Chinese University of Hong Kong | Completed | Missed primary |
| Phase 2 | NCT00404183 | Aug 2004 → Mar 2005 | — | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00371696 | Dec 2001 → Dec 2003 | osteoarthritis | University of Bristol | Completed | No outcome recorded |
| Phase 2 | NCT00029770 | Sep 2001 → May 2007 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | Met primary |
| Phase 2 | NCT00003346 | Nov 1997 → Feb 2003 | cutaneous melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00012857 | ? → Mar 2001 | Alzheimer disease | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2/313 trials · 1 missed | ||||||
| Phase 2/3 | NCT06653465 | Jun 2025 → Jun 2027 expected | delirium | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04939987 | Aug → Oct 2022 | — | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04986839 | Sep 2021 → Dec 2023 | patent ductus arteriosus | Manchester University NHS Foundation Trust | Unknown | Missed primary |
| Phase 2/3 | NCT04414995 | Jun → Nov 2020 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2/3 | NCT04360135 | May 2020 → Mar 2021 | — | Montefiore Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04038307 | Aug 2019 → Feb 2020 | — | Cairo University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03786029 | Apr → Jun 2019 | — | Latakia University | Completed | No outcome recorded |
| Phase 2/3 | NCT03825809 | Jan 2019 → Jan 2020 overdue | substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03818932 | Jan 2019 → Jan 2020 | — | Henry Ford Health System | Completed | Mixed |
| Phase 2/3 | NCT03185143 | Jun 2017 → May 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2/3 | NCT02056223 | Jan 2017 → Oct 2019 | patent ductus arteriosus, respiratory distress syndrome in premature infants | University of Padova | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01328808 | Oct 2011 → Oct 2021 | — | John van den Anker | Unknown | No outcome recorded |
| Phase 2/3 | NCT00525967 | Feb 2006 → Oct 2007 | cancer | Faculdade de Medicina do ABC | Unknown | No outcome recorded |
| Phase 398 trials · 12 met primary · 9 missed | ||||||
| Phase 3 | NCT07225634 | Sep 2026 → Mar 2027 expected | — | AFT Pharmaceuticals, Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06994442 | Dec 2025 → Jul 2029 expected | acute respiratory failure | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 3 | NCT07017452 | Aug → Dec 2025 overdue | benign prostatic hyperplasia | University of Manitoba | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06721819 | Jun 2025 → Jun 2029 expected | delirium | Beth Israel Deaconess Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05118672 | Mar → Aug 2025 | influenza | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT07323914 | Mar 2025 → Jan 2027 expected | Alzheimer disease | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 3 | NCT05070650 | Sep 2024 → Apr 2025 | common cold | Sandoz | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT06863636 | Sep 2024 → Oct 2025 overdue | osteoarthritis, hip, osteoarthritis, knee | Laboratorios Silanes S.A. de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT05845008 | Jan → Jul 2024 | — | Johnson & Johnson Consumer Inc. (J&JCI) | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT05868122 | Sep 2023 → May 2024 | — | Johnson & Johnson Consumer Inc. (J&JCI) | Completed | No outcome recorded |
| Phase 3 | NCT05246644 | Jun 2023 → Sep 2024 | delirium | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Phase 3 | NCT05761574 | May 2023 → May 2024 | — | Johnson & Johnson Consumer Inc. (J&JCI) | Completed | No outcome recorded |
| Phase 3 | NCT04251351 | Dec 2021 → Jun 2024 | Plasmodium falciparum malaria, acute kidney injury | University of British Columbia | Unknown | No outcome recorded |
| Phase 3 | NCT05051735 | Oct 2021 → Feb 2026 | cancer | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04959591 | Jun 2021 → Apr 2022 | scoliosis | Asan Medical Center | Completed | Met primary |
| Phase 3 | NCT04640376 | Mar 2021 → Nov 2022 | — | Unither Pharmaceuticals, France | Completed | No outcome recorded |
| Phase 3 | NCT02985671 | Jan → Sep 2021 | — | Ache Laboratorios Farmaceuticos S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT04429022 | Nov 2020 → May 2022 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT04093219 | Aug 2020 → Mar 2026 | coronary artery disorder, delirium | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04176419 | Jan 2020 → Jun 2021 | — | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT03508167 | Jan → Oct 2020 | — | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04038346 | Oct 2019 → May 2025 | Lyme disease, arthritic joint disease | Desiree Neville, MD | Terminated | No outcome recorded |
| Phase 3 | NCT04005755 | Jul 2019 → Jun 2020 | — | AFT Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03907176 | Apr 2019 → Oct 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03553498 | Nov 2018 → May 2019 | — | Albert Einstein College of Medicine | Completed | Missed primary |
| Phase 3 | NCT03554018 | Oct 2018 → Sep 2019 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03584373 | Jul 2018 → Mar 2022 | nephrolithiasis | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03586934 | Jun 2018 → Jun 2019 | substance-related disorder | Rush University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03485625 | Mar 2018 → Apr 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT03404518 | Feb → Oct 2018 | — | Loma Linda University | Completed | No outcome recorded |
| Phase 3 | NCT03343392 | Nov → Dec 2017 | — | Universidade Estadual de Ponta Grossa | Completed | No outcome recorded |
| Phase 3 | NCT03330119 | Oct 2017 → Jun 2018 | pregnancy disorder, substance-related disorder | Brest, Norman A., M.D. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03657810 | Aug 2017 → Apr 2018 | — | Charleston Laboratories, Inc | Completed | Mixed |
| Phase 3 | NCT03224403 | Jul 2017 → Apr 2018 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | Met primary |
| Phase 3 | NCT04037514 | Jul 2017 → Dec 2024 | patent ductus arteriosus | Máximo Vento Torres | Completed | No outcome recorded |
| Phase 3 | NCT02737124 | Feb 2017 → Mar 2018 | — | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 3 | NCT02678234 | Feb → Apr 2017 | respiratory tract infectious disorder | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT02730364 | Feb → Apr 2017 | respiratory tract infectious disorder | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT03056391 | Oct 2016 → Feb 2018 | malaria | Menzies School of Health Research | Completed | Missed primary |
| Phase 3 | NCT03024814 | Oct 2016 → Oct 2018 | intracerebral hemorrhage | King Saud Medical City | Unknown | No outcome recorded |
| Phase 3 | NCT04762147 | Oct 2016 → Jun 2017 | — | Aga Khan University | Completed | No outcome recorded |
| Phase 3 | NCT03192566 | Aug 2016 → Aug 2024 | obesity disorder | Children's National Research Institute | Suspended | No outcome recorded Stop: Business |
| Phase 3 | NCT03131713 | Jul 2016 → Dec 2017 | skin cancer | Tufts Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03537144 | Jun 2016 → Sep 2018 | patent ductus arteriosus | University of Tennessee | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02735122 | Apr → Oct 2016 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 3 | NCT02477007 | Dec 2015 → Nov 2018 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02487108 | Aug 2015 → Mar 2016 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Met primary |
| Phase 3 | NCT02311881 | Jan 2015 → Feb 2016 | — | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT02156154 | Dec 2014 → Mar 2019 | — | The Cleveland Clinic | Completed | Missed primary |
| Phase 3 | NCT02462850 | Oct 2014 → Jan 2015 | — | Charleston Laboratories, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01973205 | Oct 2013 → Jul 2014 | migraine disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01448057 | Jul 2013 → Aug 2015 | Achoo syndrome, nasal cavity disorder, respiratory tract infectious disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01842633 | Apr 2013 → Mar 2015 | — | GlaxoSmithKline | Terminated | Missed primary |
| Phase 3 | NCT01606319 | Feb 2013 → Apr 2015 | asthma | Milton S. Hershey Medical Center | Completed | Missed primary |
| Phase 3 | NCT01755728 | Jan 2013 → Dec 2018 | patent ductus arteriosus | Hillel Yaffe Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01780428 | Jan → Oct 2013 | — | Charleston Laboratories, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01722864 | Nov 2012 → Feb 2013 | chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT01635101 | Jun 2012 → Aug 2015 | — | Mallinckrodt | Completed | Missed primary |
| Phase 3 | NCT01421433 | May → Aug 2012 | — | Farmoquimica S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT01586962 | May 2012 | respiratory tract infectious disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01586143 | May 2012 → May 2013 | — | University Hospital, Clermont-Ferrand | Completed | Met primary |
| Phase 3 | NCT01402375 | Jan 2012 → Nov 2014 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01451385 | Sep 2011 → Jun 2012 | osteoarthritis | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT01432977 | Sep 2011 → Jun 2012 | pain agnosia | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 3 | NCT01394718 | Jul 2011 → Jun 2014 | — | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 3 | NCT01115673 | Jun 2010 → Jan 2011 | — | McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. | Completed | Met primary |
| Phase 3 | NCT01112267 | May → Oct 2009 | — | Janssen Korea, Ltd., Korea | Completed | Met primary |
| Phase 3 | NCT01229449 | Jan → Sep 2009 | — | Reckitt Benckiser Inc. | Completed | Met primary |
| Phase 3 | NCT00736853 | Jun 2008 → Jan 2009 | — | Janssen Pharmaceutical K.K. | Completed | Met primary |
| Phase 3 | NCT00736957 | May 2008 → Oct 2009 | chronic pain syndrome | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00662818 | Mar 2008 → Sep 2009 | heart disorder, migraine disorder, peripheral vascular disease, transient ischemic attack | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT00737048 | Mar → Sep 2008 | — | Janssen Pharmaceutical K.K. | Completed | Met primary |
| Phase 3 | NCT00573170 | Feb 2008 → Aug 2009 | migraine disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00598702 | Jan → Dec 2008 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00598559 | Jan → Nov 2008 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00564486 | Nov 2007 → Sep 2008 | — | Mallinckrodt | Completed | Met primary |
| Phase 3 | NCT00564629 | Aug → Oct 2007 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00496015 | Jul 2007 → Mar 2008 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00493311 | Jun → Oct 2007 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00406679 | Nov 2006 → Oct 2007 | neuropathy, painful | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00399568 | Nov 2006 → Sep 2007 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00434681 | Oct 2006 → Apr 2007 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00370318 | Sep 2006 → Apr 2007 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00325949 | May 2006 → May 2007 | chronic pain syndrome | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00300924 | Mar 2006 → Jan 2007 | migraine disorder | Diamond Headache Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00147355 | Nov 2005 → Nov 2008 | HIV infectious disease | Kirby Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00210847 | Dec 2003 → May 2005 | diabetic polyneuropathy | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Met primary |
| Phase 3 | NCT00236535 | Dec 2003 → Oct 2004 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00092326 | Jun → Sep 2002 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00092313 | Jun → Sep 2002 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00240786 | Apr 2002 → Mar 2003 | osteoarthritis | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 3 | NCT00390260 | Feb 2002 → Feb 2003 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00110474 | May 2000 → Dec 2002 | osteoarthritis, knee | Rottapharm | Completed | Met primary |
| Phase 3 | NCT00568295 | Oct 1999 → Oct 2000 | osteoarthritis, knee | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 3 | NCT02183688 | Sep 1998 → Jan 2003 | migraine disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00000425 | Jul 1996 → Apr 2001 | osteoarthritis | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT00240799 | ? → Oct 2004 | osteoarthritis | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | Mixed |
| Phase 3 | NCT00240773 | ? → Jun 2003 | osteoarthritis, hip, osteoarthritis, knee | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4203 trials · 17 met primary · 16 missed | ||||||
| Phase 4 | NCT07855575 | Nov 2026 → Nov 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07840183 | Sep 2026 → Sep 2027 expected | — | Northwestern University | Recruiting | No outcome recorded |
| Phase 4 | NCT07571252 | Sep → Dec 2026 expected | — | University of Puerto Rico | Recruiting | No outcome recorded |
| Phase 4 | NCT07536425 | Apr 2026 → Oct 2027 expected | — | Western Galilee Hospital-Nahariya | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07512297 | Apr → Dec 2026 expected | nephrolithiasis, ureterolithiasis | University of Gaziantep | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07368738 | Apr 2026 → Apr 2027 expected | — | Horizon Health Network | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07440069 | Feb → Aug 2026 overdue | — | Universidad Nacional Autonoma de Honduras | Recruiting | No outcome recorded |
| Phase 4 | NCT07235995 | Dec 2025 → Jan 2027 expected | delirium | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07169227 | Sep → Oct 2025 overdue | — | Baskent University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06950840 | Aug 2025 → May 2027 expected | chorioamnionitis | Wolfson Medical Center | Not yet recruiting | No outcome recorded |
| Show all 203 trials opens the full record — a long page | ||||||
| Phase not applicable98 trials · 6 met primary · 7 missed | ||||||
| — | NCT07435493 | Nov 2026 expected | adenoid hypertrophy, obstructive sleep apnea syndrome | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07539961 | Sep 2026 → Dec 2027 expected | calcific tendinitis | University Hospital Dubrava | Not yet recruiting | No outcome recorded |
| — | NCT07426744 | Mar → Aug 2026 overdue | — | Muhammad Aamir Latif | Not yet recruiting | No outcome recorded |
| — | NCT07463482 | Mar → Sep 2026 overdue | — | Thammasat University | Not yet recruiting | No outcome recorded |
| — | NCT07618494 | Feb → May 2026 | dental pulp disorder | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT07264309 | Nov 2025 → Dec 2026 expected | — | Zohar Nachum | Recruiting | No outcome recorded |
| — | NCT07310524 | Sep → Nov 2025 | — | Muhammad Rahman Efendi Nasution | Completed | No outcome recorded |
| — | NCT07154433 | Sep 2025 → May 2026 | osteochondritis dissecans | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT06917118 | May → Nov 2025 overdue | — | University of Puerto Rico | Not yet recruiting | No outcome recorded |
| — | NCT06767969 | May 2025 → Jan 2027 expected | ischemic stroke | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06430697 | Feb 2025 → Aug 2027 expected | — | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| — | NCT07368790 | Oct 2024 → May 2025 | — | Queen Savang Vadhana Memorial Hospital, Thailand | Completed | No outcome recorded |
| — | NCT07125911 | Apr 2024 → Apr 2025 | periapical periodontitis | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06304181 | Mar → Aug 2024 | — | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Unknown | No outcome recorded |
| — | NCT06174363 | Dec 2023 → Dec 2025 overdue | breast cancer | Yonsei University | Recruiting | No outcome recorded |
| — | NCT06015711 | Aug 2023 → Aug 2026 overdue | substance-related disorder | Ajou University School of Medicine | Recruiting | No outcome recorded |
| — | NCT05757388 | Mar → May 2023 | — | Khon Kaen University | Unknown | No outcome recorded |
| — | NCT05685342 | Feb 2023 → Feb 2025 | — | Seoul National University Hospital | Completed | Missed primary |
| — | NCT06638086 | Jan 2023 → Jan 2024 | — | Rawalpindi Medical College | Completed | No outcome recorded |
| — | NCT06188143 | Dec 2022 → Jun 2023 | — | Phramongkutklao College of Medicine and Hospital | Completed | No outcome recorded |
| — | NCT07394491 | Nov 2022 → Feb 2023 | — | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT05366777 | Oct 2022 → Jul 2023 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT05509244 | Sep 2022 → Aug 2023 | female reproductive system disorder | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05396677 | Mar 2022 → Jun 2023 | — | University of Guelph | Completed | No outcome recorded |
| — | NCT04593160 | Mar 2022 → Oct 2024 | pulpitis | Cairo University | Completed | No outcome recorded |
| — | NCT05248152 | Jan 2022 → Jan 2024 | — | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT04933058 | Dec 2021 → Oct 2022 | female infertility due to oocyte meiotic arrest | Tel-Aviv Sourasky Medical Center | Completed | Met primary |
| — | NCT06574516 | Nov 2021 → Aug 2022 | — | King Abdullah University Hospital | Completed | No outcome recorded |
| — | NCT05069311 | Oct 2021 → Mar 2022 | chronic pain syndrome, inflammatory disease | Udayana University | Completed | No outcome recorded |
| — | NCT04882202 | Oct 2021 → Dec 2024 | aortic disorder | Gangnam Severance Hospital | Unknown | No outcome recorded |
| — | NCT04935515 | Apr → May 2021 | COVID-19 | Manimarane Arjunan, MD,DM (Cardiology) | Completed | No outcome recorded |
| — | NCT04793490 | Mar → Nov 2021 | intracranial hypotension | Ain Shams University | Completed | No outcome recorded |
| — | NCT04566250 | Feb 2021 → Apr 2022 | — | McMaster University | Completed | Met primary |
| — | NCT04690673 | Jan → Mar 2021 | — | Johanna Kujala | Completed | No outcome recorded |
| — | NCT04202406 | Jan → May 2021 | pulpitis | Cairo University | Completed | No outcome recorded |
| — | NCT04653506 | Nov 2020 → Jul 2022 | — | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT04087317 | Jun 2020 → Jun 2022 | postpartum depression, substance-related disorder | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT05393414 | Nov 2019 → Mar 2020 | — | University of Puerto Rico | Completed | No outcome recorded |
| — | NCT04042948 | Jun → Nov 2019 | lumbar disk disease, lumbar spinal stenosis, radiculopathy | Peking University Third Hospital | Completed | No outcome recorded |
| — | NCT03859102 | Dec 2018 → Oct 2019 | aneurysm or dilatation of ascending aorta, aortic valve disorder, cardiac valvular defect, coronary artery disorder +2 | James Cook University Hospital | Unknown | No outcome recorded |
| — | NCT04202224 | Oct 2018 → Feb 2019 | — | Lithuanian University of Health Sciences | Completed | No outcome recorded |
| — | NCT03644147 | Aug 2018 → Jan 2021 | female reproductive system disorder | Seoul National University Hospital | Completed | Missed primary |
| — | NCT03413371 | Apr 2018 → Dec 2022 | — | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT04176783 | Mar 2018 → Jul 2021 | — | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| — | NCT03389243 | Jan 2018 → Sep 2021 | — | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT04003350 | Dec 2017 → Nov 2018 | osteoarthritis, knee | Rothman Institute Orthopaedics | Completed | Missed primary |
| — | NCT03400111 | Sep 2017 → Mar 2019 | malposition of teeth with or without hypodontia/oligodontia | Damascus University | Completed | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT03105830 | May 2017 → Apr 2018 | — | Western Galilee Hospital-Nahariya | Unknown | No outcome recorded |
| — | NCT03008876 | Jan 2017 → Jun 2019 | patent ductus arteriosus | Albany Medical College | Completed | No outcome recorded |
| — | NCT03011567 | Jan 2017 → Oct 2019 | hypertension, pregnancy-induced | MemorialCare Health System | Completed | Missed primary |
| — | NCT03297073 | Nov 2016 → Apr 2018 | liver disorder, paracetamol poisoning | University Hospital, Lille | Completed | No outcome recorded |
| — | NCT03122561 | Nov 2016 → Jan 2018 | — | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| — | NCT03035045 | Nov 2016 → Jun 2017 | — | Department of Medical Services Ministry of Public Health of Thailand | Unknown | No outcome recorded |
| — | NCT02833584 | Sep 2016 → Dec 2017 | dengue disease, liver disorder | Phramongkutklao College of Medicine and Hospital | Completed | No outcome recorded |
| — | NCT02700451 | Mar 2016 → Dec 2021 | lumbar disk disease, osteoarthritis, spine, spinal stenosis, spondylosis | Hospital for Special Surgery, New York | Completed | Met primary |
| — | NCT03391284 | Feb 2016 → Feb 2018 | — | Scripps Health | Completed | No outcome recorded |
| — | NCT02973581 | Feb 2016 → Feb 2017 | — | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT02440399 | Jul 2015 → May 2017 | — | HaEmek Medical Center, Israel | Completed | Missed primary |
| — | NCT02205983 | Jan 2015 → Jul 2016 | — | University of Chicago | Completed | No outcome recorded |
| — | NCT02252419 | Oct 2014 → Feb 2015 | pharyngitis | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02219698 | Jul 2014 → Jul 2015 | diverticulitis | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT02881996 | Jun 2014 → Jun 2016 | appendicitis | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| — | NCT02402543 | Jun 2014 → May 2017 | anal fistula, anogenital human papillomavirus infection, hemorrhoid | University of Vermont | Completed | No outcome recorded |
| — | NCT01982799 | Feb 2014 → Sep 2015 | tooth disorder | University of Minnesota | Withdrawn | No outcome recorded Stop: Business |
| — | NCT02267772 | Jan 2014 → Apr 2019 | — | The University of Texas Health Science Center, Houston | Terminated | Missed primary Stop: Enrollment |
| — | NCT03261310 | May 2013 → Jul 2018 | — | Brooke Army Medical Center | Unknown | No outcome recorded |
| — | NCT02750696 | Apr 2013 → Dec 2014 | suppurative periapical periodontitis | Federal University of Rio Grande do Sul | Completed | No outcome recorded |
| — | NCT01822821 | Mar 2013 → Dec 2014 | — | The Cleveland Clinic | Completed | Mixed |
| — | NCT01823224 | Feb 2013 → Jun 2015 | gallbladder disorder | Defense and Veterans Center for Integrative Pain Management | Completed | No outcome recorded |
| — | NCT01764048 | Nov 2012 → Jan 2014 | — | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT02622802 | Nov 2012 → Dec 2016 | pregnancy disorder | University Hospital, Gasthuisberg | Completed | No outcome recorded |
| — | NCT01641289 | Jul 2012 → Sep 2014 | malaria | University of Oxford | Completed | Met primary |
| — | NCT01608308 | Jul 2012 → Sep 2014 | chronic rhinosinusitis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| — | NCT01527942 | Mar 2012 → Jul 2013 | obesity disorder | Trinity Health Of New England | Terminated | No outcome recorded |
| — | NCT01552993 | Mar → Oct 2012 | pulmonary immaturity, retinopathy of prematurity | St. Olavs Hospital | Terminated | No outcome recorded |
| — | NCT01073748 | Mar 2010 → Mar 2011 | asthma | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT00970450 | Nov 2009 → Mar 2010 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT01137591 | Apr 2009 → ? | acute liver failure, drug-induced liver injury | Columbia University | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00386243 | Dec 2007 → May 2012 | chronic pain syndrome | VA Office of Research and Development | Completed | Met primary |
| — | NCT01073709 | Nov 2007 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT00561288 | Nov 2007 → May 2008 | — | University of Toronto | Completed | No outcome recorded |
| — | NCT01079078 | Oct → Nov 2007 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT01366313 | Sep 2007 → Mar 2011 | — | Procare Riaya Hospital | Completed | No outcome recorded |
| — | NCT00536068 | Aug 2006 → Aug 2007 | vascular hemostatic disease | Kantonsspital Graubünden | Completed | No outcome recorded |
| — | NCT01513668 | May 2006 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT01523080 | May 2006 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT00389272 | Sep 2005 → Dec 2008 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| — | NCT00245375 | Jan → Dec 2005 | gallbladder disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| — | NCT00253773 | Jan 2005 → Nov 2007 | disorder of defective peroxisome oxidative status | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| — | NCT01321710 | Dec 2004 → May 2008 | pregnancy disorder, puerperal disorder, sleep disorder | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00646906 | Jun 2004 → Jan 2012 | arthritic joint disease, myocardial infarction | University of Pennsylvania | Completed | Missed primary |
| — | NCT01762891 | Mar 2003 → Jul 2006 | antiphospholipid syndrome | Hospital Universitario Pedro Ernesto | Completed | No outcome recorded |
| — | NCT00137059 | Nov 2002 → May 2005 | poisoning | Dr. Marco L.A. Sivilotti | Completed | Met primary |
| — | NCT00474721 | Nov 2002 → Feb 2004 | — | University of California, San Diego | Completed | No outcome recorded |
| — | NCT00188071 | Sep 2002 → Aug 2003 | — | University Hospital, Angers | Completed | No outcome recorded |
| — | NCT00429624 | Sep 1994 → Jan 2007 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00000731 | ? → May 1990 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy865 trials | ||||||
| Phase 0 | NCT07711522 Background | Aug 2026 → Jul 2027 expected | — | Istanbul Medipol University Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07211399 Background | Jul 2026 → Dec 2030 | substance-related disorder | Jacques E. Chelly | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT07400471 Comparator | Feb 2026 → Mar 2027 expected | — | Chattogram International Dental College | Recruiting | No outcome recorded |
| Phase 0 | NCT06642025 Background | Sep 2024 → Aug 2026 overdue | acute myeloid leukemia | Zhimin Zhai | Recruiting | No outcome recorded |
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Show all 865 trials opens the full record — a long page | ||||||
Press releases naming this drug 12 releases
Evidence & citations 162 cited values
Every value below carries the sentence it was read from. 1,468 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | acetaminophen | “Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions:...” NCT07252739 ↗889“Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related...” NCT07227597 ↗ “The primary objective of this study is to evaluate the analgesic efficacy of hydrocodone bitartrate/acetaminophen immediate-release tablets at doses of 5.0 milligrams (mg)/325...” NCT02487108 ↗ “Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014 “Biphasic immediate-release (IR)/extended-release (ER) hydrocodone bitartrate (HB)/acetaminophen (APAP) 7.5/325-mg tablets are formulated with gastroretentive ER drug delivery...” PMID 26614499 ↗ Nov 2015 “The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior...” NCT00245375 ↗ “Recommended rescue medications are pegfilgrastim or equivalent, histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent,...” NCT07419295 ↗ “patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy, Cascavel, PR, Brasil) and ketorolac tromethamine oral 10 mg (Toragesic® 10...” NCT03343392 ↗ “A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites...” NCT05563961 ↗ “This clinical trial is being conducted to compare concentrations of hydrocodone and acetaminophen in the blood after administration of different amounts of tablets of a new and...” NCT03137030 ↗ “After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications,...” NCT03471442 ↗ |
| Known as | Abdine | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acamol | “Paracetamol (Acamol) 1,000 mg administered intravenously after induction of anesthesia, prior to oocyte retrieval.” NCT07536425 ↗ |
| Known as | ACE | “Acetaminophen (ACE) (1000 mg)” NCT02320708 ↗ |
| Known as | Acephen | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen (APAP) | “Acetaminophen (APAP)” NCT07101445 ↗ |
| Known as | acetaminophen / paracetamol | “acetaminophen / paracetamol” NCT03604796 ↗ |
| Known as | Acetaminophen component of allay | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of anexsia | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of anoquan | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of apadaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of bancap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of bancap hc | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of bucet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of butapap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of co-gesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of codrix | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of combogesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of combogesic iv | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of darvocet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of dhc plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of dolene ap-65 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of drixoral plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of duradyne dhc | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of esgic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of excedrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of femcet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of fioricet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of hy-phen | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of lorcet-hd | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of lortab | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of medigesic plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of norcet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of norco | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of oxycet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of percocet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of phrenilin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of roxicet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of roxilox | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of sedapap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of synalgos-dc-a | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of talacen | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of tencon | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of trezix | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of triad | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of triaprin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of tycolet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of tylox | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of ultracet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of vicodin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of wygesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of xartemis | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of zydone | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen ER | “CONCLUSIONS: Acetaminophen ER 1300 mg, a nonprescription drug, given three times daily, can provide effective relief of signs and symptoms of osteoarthritis of the hip or knee...” PMID 25121804 ↗ Aug 2014 |
| Known as | acetaminophen extended release | “acetaminophen extended release caplets, 3900 mg/day (two 650 mg caplets taken three times a day, for four days)” NCT00240851 ↗ |
| Known as | Acetaminophen/Tylenol | “Acetaminophen: Tylenol” NCT00841841 ↗1“Acetaminophen/Tylenol” NCT02029235 ↗ |
| Known as | acetaminophene | “acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die” NCT01345162 ↗ |
| Known as | acetominophen | “Drug: acetominophen” NCT03391284 ↗ |
| Known as | acetyl-para-aminophenol | “Intravenous acetyl-para-aminophenol (APAP, also known as acetaminophen) is considered as the non-opioid analgesic of choice to treat postoperative mild and moderate pain” NCT01608308 ↗ |
| Known as | ACP-iv | “the intravenous (iv) formulation (acetaminophen iv; ACP-iv) received US Food and Drug Administration (FDA) approval in November 2010” NCT02452320 ↗ |
| Known as | Alvedon | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Angiers | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | APAP | “Biphasic immediate-release (IR)/extended-release (ER) hydrocodone bitartrate (HB)/acetaminophen (APAP) 7.5/325-mg tablets are formulated with gastroretentive ER drug delivery...” PMID 26614499 ↗ Nov 201525“acetaminophen (APAP), N-acetylcysteine (NAC) and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs...” NCT00585559 ↗ “The objective of this study was to compare the analgesic efficacy of tramadol/acetaminophen (APAP) (total dose 75 mg/650 mg) and tramadol (total dose 100 mg) for the control of...” PMID 15157685 ↗ Jun 2004 “A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years” NCT07632274 ↗ “Intravenous acetyl-para-aminophenol (APAP, also known as acetaminophen) is considered as the non-opioid analgesic of choice to treat postoperative mild and moderate pain” NCT01608308 ↗ “The proposed model involves interaction of chemical exposure (2 doses of acetaminophen, APAP, 15 mg/kg) and 2 days of sulfur amino acid- (SAA-) free diet.” NCT00253773 ↗ “Paracetamol's (APAP) mechanism of action suggests the implication of supraspinal structures but no neuroimaging study has been performed in humans.” PMID 26229445 ↗ Jul 2015 “Paracetamol (APAP), also known as acetaminophen, is the most commonly used over-the-counter analgesic for the treatment of mild-to-moderate pain.” PMID 23972577 ↗ Aug 2013 “Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.” NCT00647517 ↗ “Acetaminophen (APAP) poisoning is the most frequent cause of acute hepatic failure in the United States.” NCT01246713 ↗ “XARTEMIS XR [7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)] Extended-Release Tablets” NCT02508935 ↗ |
| Known as | APAP (acetaminophen) | “APAP (acetaminophen)” NCT01002573 ↗ |
| Known as | APAP: n-acetyl-p-aminophenol; acetaminophen; Tylenol | “APAP: n-acetyl-p-aminophenol; acetaminophen; Tylenol” NCT01137591 ↗ |
| Known as | Bernofarm | “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ |
| Known as | Biocetamol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Calpol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Calpol six plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Calpol six plus fastmelts | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Child lemsip | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Cupanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Dafalgan | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Disprol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Disprol infant | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Disprol jnr | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Disprol paed | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Doliprane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05681312 ↗ |
| Known as | Doliprane 500mg | “Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily” NCT01104337 ↗ |
| Known as | Efferalgan | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | ES-acetaminophen | “Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets...” PMID 38124555 ↗ Jan 2024 |
| Known as | Extended-Release Hydrocodone/Acetaminophen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00404183 ↗ |
| Known as | FA-acetaminophen | “Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets...” PMID 38124555 ↗ Jan 20241“This study was designed as the definitive trial evaluating the onset of pain relief of FA-acetaminophen versus these same OTC comparators.” PMID 38505928 ↗ Mar 2024 |
| Known as | Fennings | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Feverall() | “METHODS: Healthy male subjects (N = 6) were randomized to receive a single dose of IV (OFIRMEV(®) ; Cadence) 1,000 mg (15 minute infusion), PO (2 Tylenol(®) 500 mg caplets;...” PMID 22524979 ↗ Apr 2012 |
| Known as | Galpamol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | HB/APAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07102459 ↗ |
| Known as | Hedex | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Infadrops | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Infant Calpol | “Children aged 1 month up to a weight of 25 kg and scheduled for elective surgery were randomly allocated to receive a prescribed 3.6 ml.kg-1 drink of water alone (water group)...” PMID 35166373 ↗ Feb 2022 |
| Known as | Infants' feverall | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Injectapap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | IV Acetaminophen (IV APAP) | “IV Acetaminophen (IV APAP)” NCT00399568 ↗1“IV Acetaminophen (IV APAP)” NCT00598559 ↗ |
| Known as | IV-A | “Intravenous Acetaminophen (IV-A)” NCT06994442 ↗ |
| Known as | Junior parapaed | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Mandanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medinol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medinol for children | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medinol over 6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medinol under 6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medised plain | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | N-(4-hydroxyphenyl)acetamide | “Acetaminophen (N-(4-hydroxyphenyl)acetamide; paracetamol) is a mild analgesic whose main, but not sole, mechanism of action is thought to arise from inhibition of the...” NCT02452320 ↗ |
| Known as | N-acetyl-p-aminophenol | “MNK-155, a biphasic (immediate-release/extended-release) hydrocodone bitartrate/N-acetyl-p-aminophenol (acetaminophen) (IR/ER HB/APAP) 7.5/325-mg fixed-dose combination analgesic agent” PMID 25913923 ↗ Apr 2015 |
| Known as | N02B E01 Paracetamol (acetaminophen) | “N02B E01 Paracetamol (acetaminophen)” NCT00699114 ↗ |
| Known as | Neopap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | NSC-109028 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | NSC-3991 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Ofiramev | “The study drug, Ofiramev® (acetaminophen) injection is a non-salicylate antipyretic and non-opioid analgesic agent.” NCT03051932 ↗ |
| Known as | Ofirmev | “These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug.” NCT04562610 ↗5“IV Paracetamol \[Ofirmev\] introduced every 6 hours after surgery” NCT06112548 ↗ “IV acetaminophen (Ofirmev™) as adjuvant analgesia” NCT01520298 ↗ “intravenous Acetaminophen (1000 mg Ofirmev)” NCT01773005 ↗ “Acetaminophen (Ofirmev)” NCT02369211 ↗ |
| Known as | OFIRMEV(TM) | “Product Information: OFIRMEV(TM) intravenous infusion, acetaminophen intravenous infusion.” NCT03020966 ↗ |
| Known as | P-hydroxy-acetanilid | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Paldesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol | “For PDA management, participants were randomly assigned to Group A, receiving oral paracetamol (Panadol, 15 mg/kg every 6 hours for 3 days), or Group B, receiving oral ibuprofen” NCT06601114 ↗3“Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches” NCT06095258 ↗ |
| Known as | Panadol actifast | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol actifast solb | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol advan | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol jnr | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol oa | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panaleve | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panaleve 6 plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | PARA | “The reference product that the active treatments will be compared to is paracetamol (PARA) 500 mg.” NCT01938144 ↗ |
| Known as | Paracerol | “Paracetamol (Paracerol) 1 gram will be administered intravenously.” NCT03063658 ↗ |
| Known as | Paracerol (paracetamol) | “Paracerol (paracetamol)” NCT05125796 ↗ |
| Known as | paracetamol | “All patients will be submitted to the institution's standard management: multimodal analgesia with common analgesic (dipyrone 4 to 8 g / day or paracetamol 1500 to 2250 mg /...” NCT07666178 ↗574“The aim of the study was to compare the analgesic efficacy of intranasal tapentadol nasal spray 44.5mg and intravenous paracetamol 1gm during the postoperative period by Visual...” NCT05999890 ↗ “Thirty minutes before the end of surgery, nefopam 40 mg, paracetamol 1 g, and ketoprofen 100 mg will be administered intravenously, depending on the patient's comorbidities,...” NCT07207304 ↗ “A non-randomized, open-label study to investigate the effects of imatinib mesylate on the pharmacokinetics of acetaminophen/paracetamol in patients with newly diagnosed,...” NCT00428909 ↗ “patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy, Cascavel, PR, Brasil) and ketorolac tromethamine oral 10 mg (Toragesic® 10...” NCT03343392 ↗ “Eligible participants received a single dose of Co-Codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via...” NCT00281684 ↗ “An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating...” NCT05821517 ↗ “Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day,...” NCT06381063 ↗ “OBJECTIVE: To evaluate the effect of postoperative intravenous (IV) acetaminophen (paracetamol) vs placebo combined with IV propofol vs dexmedetomidine on postoperative...” PMID 30778597 ↗ Feb 2019 “Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg,...” NCT02246166 ↗ “Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine...” NCT02922075 ↗ |
| Known as | Paracetamol (Acetaminophen) | “Paracetamol (Acetaminophen)” NCT00921700 ↗1“paracetamol=acetaminophen” NCT01540838 ↗ |
| Known as | Paracetamol B. Braun | “Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi...” NCT07024199 ↗1“under the brand name Paracetamol® B. Braun, Germany” NCT03060265 ↗ |
| Known as | Paracetamol Kabi | “Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi...” NCT07024199 ↗ |
| Known as | Paracetamol UNIFLASH | “Comparison of the Analgesic Effect of a New Paracetamol Formulation (Paracetamol UNIFLASH) for Buccal Use and Two Different Doses of an Oral Paracetamol Form Controlled Versus...” NCT04640376 ↗ |
| Known as | Paracetamol: Perfalgan | “Paracetamol: Perfalgan” NCT01069055 ↗ |
| Known as | Paracetamolum | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Paramin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Parapaed jnr | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Parapaed six plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | parasetamol | “Hastaya serviste tramadol PCA ve sekiz saatte bir parasetamol uygulanmaktadır.” NCT07834502 ↗ |
| Known as | Paravict | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Parol | “1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 100 patients” NCT03918135 ↗3“1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients” NCT03768882 ↗ “1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)” NCT01993589 ↗ “Parol 500 mg Tablets (acetaminophen)” NCT03058224 ↗ |
| Known as | Perfalgan | “One hundred and thirty participants received either oral paracetamol and i.v. placebo (Group OP), or oral placebo and i.v. paracetamol (Perfalgan™) (Group IP).” PMID 23220855 ↗ Dec 2012 |
| Known as | Perfalgan infusion (paracetamol) | “Perfalgan infusion (paracetamol)” NCT03221998 ↗ |
| Known as | Placidex | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | PrACETAMINOPHEN INJECTION | “An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute...” NCT05557344 ↗ |
| Known as | Rimadol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Salzone | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tixymol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tramil 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tylenol | “The ice packs, Tylenol, and Toradol regimen consists of around-the-clock ice packs, around-the-clock oral acetaminophen, around-the-clock intravenous ketorolac, and intravenous...” PMID 31201808 ↗ Jun 201941“Other pain medicines, like acetaminophen (also called Tylenol) and ketorolac (also called Toradol), are available but aren't commonly used because we don't know if they help.” NCT06994442 ↗ “The purpose of this study is to see whether giving acetaminophen (the medicine in Tylenol) for routine infant vaccinations is helpful in preventing fever or other symptoms.” NCT00325819 ↗ “Acetaminophen, often referred by the brand name, Tylenol, is also used to treat minor pains but is not commonly recognized to cause damage to the stomach lining.” NCT00594867 ↗ “The addition of acetaminophen (Tylenol) to opioids in a small study in cancer patients demonstrated better pain control without an increase in side effects.” NCT00152854 ↗ “The purpose of this study is to see if acetaminophen (Tylenol) is as effective as indomethacin in closing patent ductus arteriosus in premature infants.” NCT03537144 ↗ “Paracetamol 750 mg (Tylenol© - Johnson \& Johnson), 01 tablet every 6 hours, by oral administration, for control of postoperative pain” NCT02238288 ↗ “Paracetamol suppository 350 mg (Tylenol CILAG SA, Schaffhouse, Switzerland) will be administered for children with pain scores <4.” NCT02355678 ↗ “Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given.” NCT00267293 ↗ “The subjects will be allowed to use the rescue medication if necessary: Paracetamol 500 mg (Tylenol® 500 mg).” NCT04972292 ↗ “Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery” NCT04766996 ↗ |
| Known as | Tylenol (Acetaminophen) | “Tylenol (Acetaminophen)” NCT04423107 ↗ |
| Known as | Tylenol (caplet) | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tylenol (geltab) | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tylenol Arthritis Pain | “Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)” NCT01079078 ↗1“Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)” NCT01073709 ↗ |
| Known as | Tylenol caplets | “Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)” NCT05428306 ↗ |
| Known as | Tylenol extra strength | “Acetaminophen (Tylenol extra strength)” NCT01420094 ↗ |
| Known as | TYLENOLÒ arthritis pain | “TYLENOLÒ arthritis pain caplets 650 mg (containing acetaminophen 650 mg)” NCT01079078 ↗ |
| Known as | Uniflash | “paracetamol Uniflash (125 mg/ 1.25 mL)” NCT05406752 ↗ |
| Known as | Vermidon | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | ΑPOTEL max | “Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes.” NCT02283203 ↗ |
| Known as | ΑPOTEL Μax | “A new formulation of paracetamol for intravenous administration has been manufactured in Greece by the industry Uni-Pharma (ΑPOTEL Μax®).” NCT02283203 ↗ |
| Action | Activate | “Vanilloid receptor opener” CHEMBL112 ↗ |
| Action | Inhibit | “acetaminophen (APAP) is a potent inhibitor of hemoprotein-catalyzed lipid peroxidation” NCT00585559 ↗1“Anandamide amidohydrolase inhibitor” CHEMBL112 ↗ |
| Modality | Small molecule | “Acetaminophen is a synthetic nonopioid p-aminophenol derivative” NCT03295214 ↗ |
| Route | Oral | “APAP orally every 8 hours” NCT00000731 ↗ |
| Target | FAAH | “Anandamide amidohydrolase inhibitor” CHEMBL112 ↗ |
| Target | TRPV1 | “Vanilloid receptor opener” CHEMBL112 ↗ |